Compare BSVN & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSVN | OABI |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.1M | 391.4M |
| IPO Year | 2018 | N/A |
| Metric | BSVN | OABI |
|---|---|---|
| Price | $45.12 | $2.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $53.67 | $4.50 |
| AVG Volume (30 Days) | 7.4K | ★ 576.9K |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.05 | $52.42 |
| Revenue Next Year | $4.05 | $64.69 |
| P/E Ratio | $36.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.61 | $1.32 |
| 52 Week High | $50.10 | $2.79 |
| Indicator | BSVN | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 43.56 |
| Support Level | $45.50 | $1.75 |
| Resistance Level | $47.99 | $2.13 |
| Average True Range (ATR) | 0.72 | 0.18 |
| MACD | 0.17 | -0.09 |
| Stochastic Oscillator | 100.00 | 8.44 |
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.